Comment on "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma" [0.03%]
关于“组蛋白去乙酰化酶抑制剂氯斯硝唑作为治疗食管鳞状细胞癌的候选药物的临床前评估”的评述
Jiong Lin
Jiong Lin
Recently, we read a paper "Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma" published in Investigational New Drugs. Quisinostat may be a promising drug ca...
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study [0.03%]
关于塞利尼索联合拓扑替康治疗晚期或转移性实体瘤患者的开放性单中心多队列Ⅰb期研究结果
Kyaw Zin Thein,Sarina A Piha-Paul,Apostolia Tsimberidou et al.
Kyaw Zin Thein et al.
Background Selinexor, a first-in-class, oral selective inhibitor of nuclear export (SINE) compound inhibits Exportin-1(XPO1), had demonstrated synergistic activity with many chemotherapies and conferred in vivo antitumor efficacy in hematol...
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models [0.03%]
一种新型合成微小核糖核酸同时抑制B7-H3和PD-L1表达并可在结直肠肿瘤模型中产生显著的抗肿瘤活性
Fanyi Meng,Yinshuang Chen,Man Yang et al.
Fanyi Meng et al.
The families of miR-34 and miR-449 share the same seed region. However, the members showed differential effects on the expression of B7-H3 and PD-L1 in HCT-116 cells. Using miR-34a as a template, the non-seed region was modified by nucleoti...
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model [0.03%]
人源化高效抗mesothelin单克隆抗体 amatuximab早期给药可抑制胰腺癌肝转移并提高吉西他滨疗效：裸鼠模型中的研究
Yuki Fujii,Hirofumi Kamachi,Fumihiko Matsuzawa et al.
Yuki Fujii et al.
Amatuximab is a promising therapeutic antibody targeting mesothelin, a 40-kDa glycoprotein that is highly expressed in pancreatic cancer. We investigated the effectiveness of early amatuximab treatment, imitating an adjuvant chemotherapy se...
Identification of novel inhibitors of GLUT1 by virtual screening and cell-based assays [0.03%]
基于虚拟筛选和细胞水平药理学验证相结合的方法发现新型GLUT1抑制剂
Xiaotong Chen,Yunshuo Zhao,Sifan Lyu et al.
Xiaotong Chen et al.
In order to fuel the uncontrolled cell proliferation and division, tumor cells reprogram the energy metabolism to Warburg effect, where glucose is preferably converted by glycolysis even in the presence of oxygen. However, the high energeti...
A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma [0.03%]
聚乙二醇重组蛋白arginase治疗肝细胞癌II期临床疗效及预测性生物标志物研究
Stephen L Chan,Paul N M Cheng,Angela M Liu et al.
Stephen L Chan et al.
Background: Pegylated recombinant human arginase (PEG-BCT-100) is an arginine depleting drug. Preclinical studies showed that HCC is reliant on exogenous arginine for growth due to the under-expression of the arginine reg...
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors [0.03%]
LY3022855-CSF-1受体抑制剂与durvalumab或tremelimumab联合治疗晚期实体瘤Ia/Ib期试验
Gerald S Falchook,Marc Peeters,Sylvie Rottey et al.
Gerald S Falchook et al.
Background LY3022855 is a recombinant, immunoglobulin, human monoclonal antibody targeting the colony-stimulating factor-1 receptor. This phase 1 trial determined the safety, pharmacokinetics, and antitumor activity of LY3022855 in combinat...
Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab [0.03%]
奥拉帕利联合贝伐珠单抗治疗弥漫中线胶质瘤成功一例
Yong Wang,Jun Xu,Ningning Luo et al.
Yong Wang et al.
Diffuse midline gliomas (DMGs), which are malignant, fast-growing and entail a poor prognosis, are a rare subtype of glial tumor. DMGs harboring H3 K27-mutation are a novel entity with a poorer prognosis than the H3 wildtype and are categor...
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation [0.03%]
伊科替尼治疗EGFR L858R和A871G复合突变肺腺癌患者的疗效观察
Lin-Ling Jin,Zhen-Zhen Wu,Yan-Li Wang et al.
Lin-Ling Jin et al.
Compound epidermal growth factor receptor (EGFR) mutations are defined as double or multiple independent mutations of the EGFR tyrosine kinase domain (TKD), in which an EGFR-tyrosine kinase inhibitor (TKI)-sensitizing mutation is identified...
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer [0.03%]
替加氟片治疗吉西他滨联合顺铂方案失效的晚期胆道癌的有效性和安全性评估
Hiroto Inoue,Akiko Todaka,Kentaro Yamazaki et al.
Hiroto Inoue et al.
Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC). S-1 is often used as a second-line therapy in clinical practice, based on the resul...